Recent developments in Miller Fisher syndrome and related disorders

Current Opinion in Neurology

Volumn 18, Issue 5, 2005, Pages 562-566

  Overall, James R ^a   Willison, Hugh J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Autoimmune neuropathy; Ganglioside; Motor nerve terminal; Treatment

Indexed keywords

ALPHA LATROTOXIN; CALPAIN; CALPASTATIN; CALPEPTIN; GANGLIOSIDE GQ 1B ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PROTEIN;

ANTIBODY SPECIFICITY; AREFLEXIA; ATAXIA; BICKERSTAFF BRAINSTEM ENCEPHALITIS; CAMPYLOBACTER JEJUNI; CLINICAL FEATURE; CLINICAL TRIAL; COMPLEMENT SYSTEM; DIAGNOSTIC TEST; ENCEPHALITIS; GUILLAIN BARRE SYNDROME; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOADSORPTION; IMMUNOMODULATION; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR TRANSMISSION; NONHUMAN; OPHTHALMOPLEGIA; PLASMAPHERESIS; PRESYNAPTIC MEMBRANE; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SCHWANN CELL;

EID: 26944477778     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000173284.25581.2f     Document Type: Review

References (44)

1. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 1997; 176 (Suppl 2):S92-S98.
2. Fisher CM. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255:57-65.
3. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992; 31:677-679.
4. Bickerstaff ER. Brainstem encephalitis: further observations on a grave syndrome with benign prognosis. BMJ 1957; 1:1384-1387.
5. Lyu RK, Tang LM, Cheng SY, et al. Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry 1997; 63:494-500.
6. Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001; 56:1104-1106.
7. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet Infect Dis 2001; 1:29-37.
8. Koga M, Yuki N, Takahashi M, et al. Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain-Barré and Fisher's syndromes. J Neuroimmunol 1998; 81:138-143.
9. Koga M, Yuki N, Tai T, Hirata K. Miller Fisher syndrome and Haemophilus influenzae infection. Neurology 2001; 57:686-691.
10. Bennetto LP, Lyons P. Miller Fisher syndrome associated with Pasteurella multocida infection. J Neurol Neurosurg Psychiatry 2004; 75:1786-1787.
11. Hsueh KC, Chou IC, Hsu CH, et al. Miller Fisher syndrome possibly related to mycoplasma pneumoniae infection: report of one case. Acta Paediatr Taiwan 2004; 45:168-170.
12. Rodriguez Uranga JJ, Delgado Lopez F, Franco Macias E, et al. [Miller-Fisher syndrome: clinical features, associated infections and clinical course in 8 cases]. Med Clin (Barc) 2004; 122:223-226.
13. Yuki N, Odaka M, Hirata K. Acute ophthalmoparesis (without ataxia) associated with anti-GQ1b IgG antibody: clinical features. Ophthalmology 2001; 108:196-200.
14. O'Leary CP, Veitch J, Durward WF, et al. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J Neurol Neurosurg Psychiatry 1996; 61:649-651.
15. Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993; 43:1911-1917.
16. Richter R. The ataxic form of polyradiculoneuritis (Landry-Guillain- Barré syndrome). J Neuropathol Exp Neurol 1962; 21:171-184.
17. Yuki N, Susuki K, Hirata K. Ataxic Guillain-Barré syndrome with anti-GQ1b antibody: relation to Miller Fisher syndrome. Neurology 2000; 54:1851-1853.
18. Yuki N, Sato S, Tsuji S, et al. An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci 1993; 118:83-87.
19. Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain 2003; 126:2279-2290.
20. Willison HJ, Veitch J, Paterson G, Kennedy PG. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry 1993; 56:204-206.
21. Yuki N, Sato S, Tsuji S, et al. Frequent presence of anti-GQ1b antibody in Fisher's syndrome. Neurology 1993; 43:414-417.
22. Susuki K, Yuki N, Hirata K. Fine specificity of anti-GQ1b IgG and clinical features. J Neurol Sci 2001; 185:5-9.
23. Kashihara K, Shiro Y, Koga M, Yuki N. IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1998; 65:799.
24. Nagashima T, Koga M, Odaka M, et al. Clinical correlates of serum anti-GT1a IgG antibodies. J Neurol Sci 2004; 219:139-145. A large series of cases detailing the clinical characteristics of GT1a positive patients.
25. Odaka M, Koga M, Yuki N, et al. Longitudinal changes of anti-ganglioside antibodies before and after Guillain-Barré syndrome onset subsequent to Campylobacter jejuni enteritis. J Neurol Sci 2003; 210:99-103.
26. Nishimoto Y, Odaka M, Hirata K, Yuki N. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol 2004; 148:200-205. A study describing the CSF findings in MFS cases and comparing these with anti-GQ1b antibody testing.
27. Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 2001; 70:50-55.
28. Hamaguchi T, Yamaguchi K, Komai K, et al. Recurrent anti-GQ1b IgG antibody syndrome showing different phenotypes in different periods. J Neurol Neurosurg Psychiatry 2003; 74:1350.
29. Roberts M, Willison H, Vincent A, Newsom-Davis J. Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release. Lancet 1994; 343:454-455.
30. Buchwald B, Dudel J, Toyka KV. Neuromuscular blockade by immunoglobulin G from patients with Miller Fisher syndrome. Ann N Y Acad Sci 1998; 841:659-669.
31. Plomp JJ, Molenaar PC, O'Hanlon GM, et al. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann Neurol 1999; 45:189-199.
32. O'Hanlon GM, Plomp JJ, Chakrabarti M, et al. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 2001; 124:893-906.
33. Slater C. Double agents and breakdown of integrity at the neuromuscular junction in Miller-Fisher syndrome. Brain 2001; 124:847-848.
34. Lo YL, Chan LL, Pan A, Ratnagopal P. Acute ophthalmoparesis in the anti-GQ1b antibody syndrome: electrophysiological evidence of neuromuscular transmission defect in the orbicularis oculi. J Neurol Neurosurg Psychiatry 2004; 75:436-440. First human in-vivo demonstration of a defect of neuromuscular transmission as determined by jitter analysis.
35. Halstead SK, O'Hanlon GM, Humphreys PD, et al. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 2004; 127:2109-2123. An experimental demonstration of the role of membrane attack complex in mediating membrane injury, including targeting of perisynaptic Schwann cells by anti-GQ1b antibody.
36. Jacobs BC, O'Hanlon GM, Bullens RW, et al. Immunoglobulins inhibit pathophysiological effects of anti-GQ1 b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 2003; 126:2220-2234.
37. O'Hanlon GM, Humphreys PD, Goldman RS, et al. Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. Brain 2003; 126:2497-2509.
38. Willison HJ, Townson K, Veitch J, et al. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. Brain 2004; 127:680-691. A proof of principle report outlining the potential role for immunoadsorption plasma exchange in selectively removing anti-GQ1b antibodies from the circulation in MFS.
39. Mori M, Kuwabara S, Fukutake T, Hattori T. Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases. J Neurol Neurosurg Psychiatry 2002; 72:680.
40. Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2002; (2):CD001798.
41. Hughes RA, Raphael JC, Swan AV, van Doom PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2004; (1):CD002063.
42. van Koningsveld R, Schmitz PI, Meche FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004; 363:192-196.
43. Overell J, Hseih T, Odaka M, et al. Treatment for Miller Fisher syndrome and other related disorders. Cochrane Database Syst Rev 2004; (2):CD004761.
44. Paparounas K. Anti-GQ1b ganglioside antibody in peripheral nervous system disorders: pathophysiologic role and clinical relevance. Arch Neurol 2004; 61:1013-1016.